Drugmakers’ Pricing Power Remains Strong

ON-BR342_Biogen_M_20160421171905

Price increases continue despite pushback from insurers, U.S. lawmakers

Pharmaceutical companies’ power to raise prices is firmly intact despite pushback from health insurers, scrutiny by U.S. lawmakers and anxiety about rising prescription drug spending.

More than two-thirds of the 20 largest​pharmaceutical companies said price increases boosted sales of some or most of their biggest ​products in the first quarter, according to a Wall Street Journal review of corporate filings and conference-call transcripts. ​​Read more here.


Leave a Reply

Your email address will not be published. Required fields are marked *


Home / Regulatory Policy Left / Drugmakers’ Pricing Power Remains Strong